Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Great buy in. You will be rewarded greatly. I'm buying in PM tomorrow. I hoping to get it under $11. Wish me luck. Should run to $15 easy.
This looks great. I read everything about it. I'm buying at least 4,000 shares on Monday.
I rode it from 7 to 14. Just bought in again at 9.40. See what happens
I think the 20M float combined w/ the the clinical collaboration w/ Astra Zeneca are game changers here. Its not eveery day that a mid cap biopharma gets a deal with one of the major pharmaceuticals. This is in a solid uptrend and I'm in the swing this week and next for the move back to the $19 mark and beyond. I believe we can have a major breakout here.
Back to single digits soon.
They need $$$ to do phase 3
And FDA Application.
This was nothing but a PUMP&DUMP.
You guessed it right, I am short this
Over valued pig.
Stay Thirsty, while we get back to reality.
Yeah played me some NLNK last week on a couple dips, but the same historic area once again proved to be the same top area again last Friday.
I still have them.
thank you fer updating/ Newlink Genetics Cor (NLNK)
18.13 ? 4.53 (33.31%)
Volume: 29,094,480 @ 3:25:40 PM EDT ET
Bid Ask Day's Range
18.13 18.16 13.51 - 19.3
NLNK Detailed Quote
MORE WOW!!
NLNK
GOOD MORNING , IT IS AH WOW/ 'NewLink Genetics Corporation (NLNK)'
Compose your message here:
wow hope you held and was able get a piece of this large gain
I know. I purchased 1000 shares a while back for $7.50.
* * $NLNK Video Chart 08-31-17 * *
Link to Video - click here to watch the technical chart video
NewLink Genetics to Participate in Upcoming Investor Conferences "GlobeNewswire Inc." - 8/29/2017 7:00:00 AM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 8/3/2017 3:51:45 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 7/28/2017 9:08:06 AM
NewLink Genetics Reports Second Quarter 2017 Financial Results and Updates Indoximod Program "GlobeNewswire Inc." - 7/28/2017 8:00:00 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 7/27/2017 7:26:45 AM
Newlink Genetics Cor (NLNK)
7.89 ? 0.79 (11.13%)
Volume: 1,558,922 @ 2:56:06 PM EDT ET
Bid Ask Day's Range
7.88 7.9 7.101 - 7.935
NLNK Detailed Quote
Newlink Genetics Cor (NLNK)
7.69 ? 0.19 (2.53%)
Volume: 641,259 @ 4:32:31 PM ET
Bid Ask Day's Range
7.1 7.86 7.5 - 7.82
NLNK Detailed Quote
$$NLNK$$ massive reversal springboard action going deep green
Looking for a rebound-reconranger
Indoximod vs Epacadostat
The main difference between the two is that Indoximod is mainly a IDO2 inhibitor, Epadostat a IDO1 inhibitor (like BMS's). Melanoma shows both IDO1 and IDO2 overexpression, whereas Pancreatic Cancer and AML have a significant IDO2 overexpression. IDO2 overxpression is high in some tumor types, for which Indoximod will have no or little competition: two of them are Pancreatic Cancer and AML, but
also gastric and colon cancers
http://www.sciencedirect.com/science/article/pii/S2452336417300201
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3176891/
http://www.bloodjournal.org/content/126/23/1191?sso-checked=true
Always dangerous to buy too early. On close watch for the next weeks. Good luck to you and enjoy your weekend!
Well took the profit and ran and bought ADSX @7.76 hope to get some good news monday
Well a little bounce back but should slowly inch lower
Maybe 4,50-5,00 - gonna need some time to settle out of experience
You may have to add a little in the next few days - unless it does bounce some tomorrow or Monday - which it may well do. Either way, GL to you.
I picked up a few thousand @6.50 hoping that it is oversold
I think you can pretty much bank on that...but...we shall see.
Indoximod vs Epacadostat
People saying that indoximod has had disappointing results vs INCY Epacadostat simply do not understand what is a double blinded trial and how immunotherapy works.
The only similar trial they had was for Naive Advanced Melanoma patients in combination with PD1 inhibitors.
Provided that comparing efficacy results in different trial is bad science, since patient populations are different in each trial, INCY Epacadostat had trials with both Nivolumab and Pembrolizumab, Indoximod only with Pembrolizumab.
The results are reported below (for non ocular melanoma):
1) EPA plus PEMBRO n. 19 patients ORR 58% (CR 26% PR 36%)
2) EPA plus NIVO n. 40 patients ORR 63% (CR 5% PR 58%)
2) INDO plus PEMBRO n. 51 patients ORR 59% (CR 12% PR 47%)
Pembro and Nivo have shown to be equivalent PD1 inhibitors as monotherapy in many melanoma trials, with a slight advantage for Nivo , if any.
This is also evident to me looking at the two EPA combinations where ORR was quite similar and the same was also for Indomixod trial.
I would not put too much weight on the higher CR for EPA plus Pembro since it is a smaller and older trial and I am sure that more PR with other two trials will become CR with time. This is normal with immunotherapies that need time to show efficacy and have long duration of response.
So all in all, in the only almost comparable trials i have seen so far I do not think that Indoximod is an inferior product to Epacadostat at all.
With the only difference that INCY is a $24B market cap company (at least half of which due to Epacadostat potential) and NLNK is less than $200M company (with $100M plus in cash).
This without even considering the other IDO inhibitor ROCHE has today declined to develop further and on which NLNK has regained its global rights (after getting $150M cash btw).
In any case IDO inibition has a future with PD1 inhibitors in many cancers with or without chemotherapy or as an alternative to PD1 inhibitor with chemotherapy and it is far too early to write off NLNK Indoximod, this could be as big as Epacadostat fetching many billions in annual revenue each.
GREAT POINT PARTNERS LLC has filed a new 13G, reporting 5.13% ownership in $NLNK - https://fintel.io/so/us/nlnk and https://fintel.io/i/great-point-partners-llc
NLNK News: Current Report Filing (8-k) 05/18/2017 08:21:21 AM
NLNK News: Data from Clinical Study of NewLink Genetics’ IDO Pathway Inhibitor, Indoximod, to Be Presented at the 22nd European Hemato... 05/18/2017 06:00:00 AM
NLNK News: Current Report Filing (8-k) 05/17/2017 05:14:03 PM
NLNK News: Data from Clinical Studies of NewLink Genetics’ Two Distinct IDO Pathway Inhibitors to Be Presented at ASCO 2017 05/17/2017 05:05:00 PM
NLNK News: Current Report Filing (8-k) 05/17/2017 04:20:56 PM
Newlink Genetics Cor (NLNK)
15.5 ? 0.0 (0.00%)
Volume: 0 @- ET
Bid Ask Day's Range
10.15 26.0 - - -
NLNK Detailed Quote
NewLink Genetics Announces Presentation of Two Abstracts at ASCO
http://finance.yahoo.com/news/newlink-genetics-announces-presentation-two-110000255.html
Newlink Genetics Cor (NLNK)
16.19 ? -1.35 (-7.70%)
Volume: 1,542,377 @ 4:28:55 PM ET
Bid Ask Day's Range
10.5 16.21 15.6 - 17.5
NLNK Detailed Quote
Interim Phase 2 Data Demonstrate Robust Response Rate with Indoximod in Combination with Keytruda® (pembrolizumab) for Patie...
Newlink Genetics Corp. (MM) (NASDAQ:NLNK)
Intraday Stock Chart
Today : Tuesday 4 April 2017
Click Here for more Newlink Genetics Corp. (MM) Charts.
NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical company focused on bringing novel immuno-oncology therapies to patients with cancer, today reported interim results from NLG2103, a Phase 2 study evaluating its IDO pathway inhibitor, indoximod, in combination with checkpoint inhibitors for the treatment of patients with advanced melanoma.
An infographic accompanying this release is available at
http://www.globenewswire.com/NewsRoom/AttachmentNg/f025a8a3-f8c5-4cf6-972b-e57312023126
These data report on a cohort of 60 evaluable patients (including patients with ocular melanoma) who received the combination of indoximod plus pembrolizumab which demonstrated a 52% (31/60) ORR and a 73% (44/60) DCR. Patients with non-ocular melanoma achieved a 59% (30/51) ORR and an 80% (41/51) DCR. The combination was generally well tolerated with low rates of Grade 3 or higher adverse events. These data will be presented today in the Clinical Trials Plenary Session at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, D.C.
“These data are impressive and demonstrate the potential of this combination to improve response rates of the currently available therapy for patients with advanced melanoma. Importantly, our combination therapy was well tolerated without an appreciable increase in toxicity,” said Dr. Yousef Zakharia, M.D., Assistant Professor of Medicine, Division of Hematology, Oncology and Blood & Marrow Transplantation at the University of Iowa and Holden Comprehensive Cancer Center, a leading investigator on the trial.
Nicholas Vahanian, M.D., President and Chief Medical Officer said, “These new data further underscore the potential for indoximod in combination with other agents. The ORR and DCR are highly encouraging and further validate indoximod as a promising IDO pathway inhibitor.”
Charles J. Link, Jr., M.D., Chairman and Chief Executive Officer said, "Currently approved immunotherapies are transforming cancer treatment. We believe targeting the IDO pathway is key to enhancing the efficacy of existing and future treatment regimens. NewLink Genetics has two distinct IDO pathway inhibitors in development that represent separate and independent opportunities. We expect further clinical validation of the IDO pathway as an immuno-oncology target throughout 2017.”
NLG2103 is a Phase 2 study evaluating the addition of indoximod to the standard of care checkpoint inhibitors approved for patients with advanced melanoma (pembrolizumab, ipilimumab, or nivolumab). The interim data represent a cohort of 60 evaluable patients who received indoximod plus pembrolizumab. Evaluable patients were defined as those having at least one on-treatment imaging study. The primary outcome measure of the trial is objective response rate (ORR) and secondary outcome measures include disease control rate (DCR) and evaluation of safety and tolerability.
Key findings:
•The ORR, by site reported RECIST criteria, for all patients was 52% (31/60) with a 73% (44/60) DCR.
•Patients with non-ocular melanoma achieved a 59% (30/51) ORR and a DCR of 80% (41/51).
•The majority of responses reported have been durable.
•The occurrence of Grade 3 or greater adverse events was low with no apparent increase for the combination over what would be expected with pembrolizumab alone.
About Indoximod
Indoximod is an investigational, orally available small molecule targeting the IDO Pathway. The IDO Pathway is one of the key immuno-oncology targets involved in regulating the tumor microenvironment and immune escape.
NewLink Genetics is currently evaluating indoximod in multiple combination studies for patients with various types of cancer. These include melanoma, acute myeloid leukemia, pancreatic cancer and prostate cancer.
About NewLink Genetics Corporation
NewLink Genetics is a biopharmaceutical company at the forefront of discovering, developing and commercializing novel immuno-oncology product candidates to improve the lives of patients with cancer. NewLink Genetics' product candidates are designed to harness multiple components of the immune system to combat cancer. For more information, please visit http://www.newlinkgenetics.com.
KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (Source)
NLNK News: Current Report Filing (8-k) 03/20/2017 08:34:26 AM
NLNK News: Annual Report (10-k) 03/06/2017 02:16:33 PM
NLNK News: Current Report Filing (8-k) 03/01/2017 05:30:40 PM
NLNK News: NewLink Genetics Announces Presentation of Two Abstracts at AACR 03/01/2017 05:05:40 PM
NLNK News: Current Report Filing (8-k) 02/28/2017 08:35:07 AM
Newlink Genetics Cor (NLNK)
20.25 ? -0.4 (-1.94%)
Volume: 290,139 @ 4:20:44 PM ET
Bid Ask Day's Range
18.88 22.5 19.44 - 20.958
NLNK Detailed Quote
Followers
|
31
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
639
|
Created
|
04/18/12
|
Type
|
Free
|
Moderators |
NewLink Genetics Corporation (NewLink) is a late-stage, biopharmaceutical company focused on discovering, developing, and
commercializing novel immunotherapeutic products to improve cancer treatment options for patients and physicians.
Our portfolio includes both "off-the-shelf" biologic and small-molecule immunotherapy product candidates intended to address large,
unmet oncology indications, including treatment of pancreatic cancer, non-small cell lung cancer (NSCLC), and melanoma.
We believe our technologies may also be useful in the field of infectious disease.
Our biologic pipeline is based on NewLink's HyperAcute® technology platform,which is designed to harness multiple components of
the innate immune system to combat cancer, either alone or in combination with other treatments, without significant incremental toxicity.
In contrast to autologous therapies, HyperAcute product candidates do not require patients to donate cellular material, which permits an
easier scale-up of the manufacturing process.
To date, HyperAcute product candidates have been administered to about 300 cancer patients and have demonstrated good tolerability and a favorable safety profile.
Our lead HyperAcute immunotherapy product candidate is being studied in a Phase 3 clinical trial in surgically-resected pancreatic cancer patients.
This trial is an open-label, randomized, controlled, multi-center, Phase 3 clinical trial evaluating approximately 700 Stage I and Stage II surgically-resected
pancreatic cancer patients, which is being performed under a Special Protocol Assessment (SPA) with the United States Food and Drug Administration (FDA).
We have also received Fast Track and Orphan Drug designations from the FDA for this product candidate for the adjuvant treatment of surgically-resected pancreatic cancer.
First and second interim analyses of data from the Phase 3 trial are expected in late 2012 and 2013, respectively, and complete enrollment is expected in 2013.
Additional HyperAcute product candidates, including both NSCLC and melanoma, are in Phase 2 clinical trials.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |